Survival
Disaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…
Read MoreAdverse Renal Outcomes in Patients With Mesothelioma-A Territory-Wide Real-World Data
Cancer Medicine 2026 February [Link] Wang Chun Kwok, James Chung Man Ho, Isaac Sze Him Leung, Desmond Yat Hin Yap Abstract Introduction: Advances in mesothelioma management have translated into longer patient survival and different treatment-related side effects including nephrotoxicity. The risk of developing adverse renal outcomes in patients with mesothelioma and associated risk factors remains…
Read MoreTreatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007-2020
Advances in Therapy 2026 March [Link] Himani Aggarwal, Ashwini Arunachalam, Jae Min, Yu-Han Kao, Haidong Feng, Danmeng Huang, Gloria Odonkor Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare malignancy typically attributed to occupational asbestos exposure and associated with dismal survival outcomes. The standard of care for unresectable MPM was platinum-based chemotherapy until the approval…
Read MoreMechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs
Archives of Medical Research 2026 January 27 [Link] Andrea Martinez-Marroquin, Javier Gaytán-Cervantes, Haydeé Rosas-Vargas, Constantino López-Macías, Itzel Peralta-Salguero, Miguel Cid-Soto, Violeta Castro Leyva, Marlon De Ita, Carolina González-Torres Abstract Malignant pleural mesothelioma (MPM), is a rare and aggressive cancer that originates in the mesothelium lining the lungs. It is considered an occupational disease associated with…
Read MorePD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma
Cells 2026 January 19 [Link] Milija Gajić, Vesna Ćeriman Krstić, Natalija Samardžić, Ivan Soldatović, Sofija Glumac, Milena Jovanović 4, Milan Savić, Mihailo Stjepanović, Spasoje Popević, Ruža Stević, Nikola Čolić, Katarina Lukić, Vladimir Milenković, Ivan Milivojević, Ivana Sekulović Radovanović, Dragana Jovanović Abstract Malignant pleural mesothelioma (MPM) is a very aggressive tumor. The prognostic value of PD-L1…
Read MorePrognostic value and clinical significance of tumoral PD-L1 and stromal α-SMA expression in diffuse pleural mesothelioma
Neoplasma 2026 February [Link] Yeqi Sun, Lan Li, Lei Cai, Jihua Yang, Jun Qian, Fajiu Wang, Lifeng Wang Abstract Diffuse pleural mesothelioma (PM) is a rare malignant neoplasm with an extremely poor prognosis. Prognostic assessment remains challenging, highlighting the urgent need for reliable biomarkers to guide precise and effective therapy. Programmed death ligand 1 (PD-L1)…
Read MoreComparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients
Oxford Open Immunology 2025 December 24 [Link] Nicola Principe, Kofi L P Stevens, Amber-Lee Phung, Melanie McCoy, Joel Kidman, Ali Ismail, Alistair M Cook, Abha Chopra, Mark Watson, Bruce W Robinson, Jenette Creaney, Y C Gary Lee, Jason Waithman, W Joost Lesterhuis, Richard A Lake, Anna K Nowak, Jonathan Chee, Alison M McDonnell Abstract The…
Read MoreCancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma
Cancer Science 2026 January 20 [Link] Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka Abstract Pleural mesothelioma (PM) is a malignancy with a poor prognosis owing to its resistance to…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read More
Skip to content